miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase

Abstract

Background Aberrant expression of microRNAs (miR) has been proposed as non-invasive biomarkers for breast cancers. The aim of this study was to analyse the miR-622 level in the plasma and in tissues of breast cancer patients and to explore the role of miR-622 and its target, the NUAK1 kinase, in this context. Methods miR-622 expression was analysed in plasma and in tissues samples of breast cancer patients by q-RT-PCR. Bioinformatics programs, luciferase assay, public dataset analysis and functional experiments were used to uncover the role of miR-622 and its target in breast cancer cells. Results miR-622 is downregulated in plasma and in tissues of breast cancer patients respect to healthy controls and its downregulation is significantly associated with advanced grade and high Ki67 level. Modulation of miR-622 affects the motility phenotype of breast cancer cells. NUAK1 kinase is a functional target of miR-622, it is associated with poor clinical outcomes of breast cancer patients and is inversely correlated with miR-622 level. Conclusions miR-622/NUAK1 axis is deregulated in breast cancer patients and affects the motility phenotype of breast cancer cells. Importantly, miR-622 and NUAK1 hold promises as biomarkers and as targets for breast cancers.

Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11

“…In recent years, miR-622 has emerged as one of the most promising tumorsuppressive microRNAs, which is underscored by numerous studies addressing its potent role in diverse types of cancer [ 13 , 17 , 18 , 20 , [38] , [39] , [40] , [41] , [42] , [43] , [44] ].…”

Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma

“…It has been demonstrated by our group and others that microRNAs (miRs) represent powerful small RNA molecules that modulate drug resistance related features in HCC [ 10 , 24 ]. In recent years, miR-622 has emerged as one of the most promising tumorsuppressive microRNAs, which is underscored by multiple studies addressing its potent role in diverse types of cancer [ 6 , 10 , 22 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ].…”

Experimental and Bioinformatic Clues to the Potential Roles of hsa_circ_0013958 and hsa_circ_0003028 in Clinopathophysiology of Breast Cancer

“…We observed that the most interactions are between the mRNAs KRAS, AKT1, SNAI2, and miR-NAs including hsa-mir-637, hsa-mir-622, and hsa-mir-545 in this network. The vital role of these mRNAs and miRNAs hsa-mir-637, hsa-mir-622 in BC has been previously revealed [23][24][25][26][27]. The hsa_circ_0003028/ miRNA/mRNA network also contained 1cir-cRNA, 22 miRNAs, and 78 mRNAs (Fig- Transcription factor products of the mRNA member of the evaluated circRNA/miRNA/ mRNA networks We found that the mRNAs with having the transcription factor role involved in the predicted regulatory hsa_circ_0013958/miRNA/ mRNA network were SNAI2 and SP7.…”